El Tribunal Supremo rechaza la oferta legal para detener el juicio de bloqueadores de la pubertad para niños

A high court judge has ruled that a clinical trial involving puberty blockers for children can proceed, dismissing a legal challenge brought by campaigners. The decision, delivered by Mr Justice Chamberlain on Friday, cleared the path for the Pathways trial, which will enroll approximately 220 children aged between 11 and 16 years old. The trial, led by researchers at King’s College London (KCL), aims to evaluate the potential benefits and risks of puberty suppression medications for children experiencing persistent gender incongruence. The legal challenge, brought by campaigners including the Bayswater Support Group, psychotherapist James Esses, and former participant Keira Bell, argued that the trial lacked adequate safeguards and ethical oversight. They claimed the long-term physical and psychological effects on children were not sufficiently understood, raising concerns about informed consent and the overall safety of the study. However, the judge rejected these arguments, stating that none of the claims had a realistic chance of success in court. He emphasized that each child enrolled in the trial would have undergone extensive assessment by specialist doctors, who would have determined that the treatment offered a reasonable prospect of clinical benefit. The Pathways trial was initiated in response to a 2024 review conducted by Baroness Hilary Cass, which highlighted the lack of robust evidence supporting the use of puberty blockers in children. The review, titled Gender Identity Services: A Review, noted that the field of gender medicine was built on "shaky foundations." Following the findings, the UK government banned the use of puberty-blocking drugs in gender care for children, allowing existing patients to continue treatment but requiring new cases to be managed within a controlled clinical trial setting. NHS England commissioned the Pathways study to gather scientific data on the potential health impacts of the drugs. According to KCL, the trial will involve children who have already accessed specialist gender services in England and have a formal diagnosis of gender incongruence. Participants must undergo thorough medical and psychological evaluations, and both the child and their family must demonstrate understanding of the treatment’s potential consequences. The trial will examine the effects of the drugs on bone density, brain development, fertility, and mental well-being. Researchers have stated that the study is designed with strict eligibility criteria and has been independently reviewed by regulatory bodies, including the Health Research Authority (HRA) and the Medicines and Healthcare products Regulatory Agency (MHRA). Despite the court’s decision, some campaigners remain unconvinced. The Bayswater Support Group, which represents parents of gender-questioning children, maintains that the trial does not meet the necessary legal and ethical standards. They argue that the study’s design, scale, and potential risks raise serious concerns about the protection of minors. Keira Bell, who took puberty blockers during adolescence before detransitioning, expressed disappointment with the ruling, stating that the medical profession and morality do not always align. She called the trial a "tragedy" and questioned whether the research should even be permitted. As the trial prepares to begin recruitment from 1 August, the focus will shift to ensuring compliance with all safety protocols and ethical guidelines. The Health Research Authority has reiterated that the trial’s safeguards are rigorous, and that the process includes independent ethics reviews and public accountability measures. With the legal hurdles removed, the Pathways trial stands as the first large-scale, controlled study examining the long-term effects of puberty blockers on children in the UK. The results of the trial are expected to provide critical insights into the medical, psychological, and social implications of the treatment for young people.